Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma
Open Access
- 1 June 2020
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 111 (6), 1899-1909
- https://doi.org/10.1111/cas.14398
Abstract
Tumor-infiltrating immune cells play a crucial role in tumor progression and response to treatment. However, the limited studies on infiltrating immune cells have shown inconsistent and even controversial results for osteosarcoma (OS). In addition, the dynamic changes of infiltrating immune cells after neoadjuvant chemotherapy are largely unknown. We downloaded the RNA expression matrix and clinical information of 80 OS patients from the TARGET database. CIBERSORT was used to evaluate the proportion of 22 immune cell types in patients based on gene expression data. M2 macrophages were found to be the most abundant immune cell type and were associated with improved survival in OS. Another cohort of pretreated OS samples was evaluated by immunohistochemistry to validate the results from CIBERSORT analysis. Matched biopsy and surgical samples from 27 patients were collected to investigate the dynamic change of immune cells and factors before and after neoadjuvant chemotherapy. Neoadjuvant chemotherapy was associated with increased densities of CD3+ T cells, CD8+ T cells, Ki67 + CD8+ T cells and PD-L1+ immune cells. Moreover, HLA-DR-CD33+ myeloid-derived suppressive cells (MDSC) were decreased after treatment. We determined that the application of chemotherapy may activate the local immune status and convert OS into an immune "hot" tumor. These findings provide rationale for investigating the schedule of immunotherapy treatment in OS patients in future clinical trials.Keywords
Funding Information
- National Natural Science Foundation of China (81702665, 81872183, 81872268)
This publication has 59 references indexed in Scilit:
- CD4+ follicular helper T cell infiltration predicts breast cancer survivalJCI Insight, 2013
- Chemoimmunotherapy: reengineering tumor immunityCancer Immunology, Immunotherapy, 2013
- Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trialsAnnals Of Oncology, 2012
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II StudyJournal of Clinical Oncology, 2012
- Osteosarcoma incidence and survival rates from 1973 to 2004Cancer, 2009
- Second and Subsequent Recurrences of Osteosarcoma: Presentation, Treatment, and Outcomes of 249 Consecutive Cooperative Osteosarcoma Study Group PatientsJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Caspase-dependent immunogenicity of doxorubicin-induced tumor cell deathThe Journal of Experimental Medicine, 2005
- Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institutionEuropean Journal Of Cancer, 2005
- The Immunobiology of Cancer Immunosurveillance and ImmunoeditingImmunity, 2004